Organisation paid for research Program year 2022 Source: CMS Open Payments

Vitreoretinal Consultants

Neither a doctor nor a teaching hospital

Research payments

$2,747,552

53 payments

Through program year 2022, Vitreoretinal Consultants is reported as receiving $2,747,552 in research payments, across 53 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$190,075	25
2021	Research	$354,283	10
2020	Research	$1,207,520	10
2019	Research	$995,674	8

Breakdown

Who paid Research payments · program years 2019–2022

Novartis Pharmaceuticals Corporation $2,143,247 9 payments
Genentech, Inc. $604,305 44 payments

Studies the money was for Research payments · program years 2019–2022

A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic MacUlar Edema $1,505,365 4 payments
A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due to MacUlar Edema (Me) Secondary to Central Retinal Vein Occlusion (Crvo) $386,875 3 payments
Va2 Phiii Yosemite $307,133 12 payments
Biomarker Ang 2 Inhibitor Study $180,841 24 payments
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $154,543 1 payment
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to MacUlar Edema Secondary to Branch Retinal Vein Occlusi $96,464 1 payment
Phase 2 of Ro7171009 in Ga $92,530 5 payments
Faricimab Dme Long Term Extension Rhone X $23,802 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.